<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-148648</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Limits of conventional oral and transdermal medication in Parkinson&#146;s disease</dc:title>
<dc:description xml:lang="en">At the present time, we have effective and potent antiparkinsonian drugs available which allow patients to have an acceptable functional capacity during the early years of Parkinson&#146;s disease. Yet, as time goes by, motor and functional deterioration develop, partly due to the presence of motor and non-motor complications. The conventional medication is unable to provide an adequate response if the motor fluctuations are beyond 3-4 hours of duration. At this point, it is reasonable to consider other therapies; among them subcutaneous apomorphine injection must be taken into account due to its simplicity and efficacy and later on, subcutaneous apomorphine infusion. Apomorphine is a very effective and clearly underused drug in the treatment of advanced Parkinson&#146;s disease (AU)</dc:description>
<dc:creator>García Ruiz, Pedro J</dc:creator>
<dc:creator>Luquín, M Rosario</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En el momento actual, contamos con medicación antiparkinsoniana eficaz y potente, lo que permite una capacidad funcional aceptable durante los primeros años de la enfermedad de Parkinson. Sin embargo, con el paso del tiempo, existe un deterioro motor y funcional en parte por la presencia de complicaciones motoras y no motoras. La medicación convencional no es capaz de dar respuesta suficiente si las fluctuaciones motoras son superiores a 3-4 horas. En ese punto es razonable evaluar otras terapias; entre ellas hay que considerar, por su sencillez y eficacia, la apomorfina en inyección subcutánea y posteriormente la apomorfina en infusión. La apomorfina es un tratamiento muy efectivo y claramente infrautilizado en la enfermedad de Parkinson avanzada (AU)</dc:description>
<dc:source>Rev Neurol;55(supl.1): s3-s6, 31 dic. 2012.</dc:source>
<dc:identifier>ibc-148648</dc:identifier>
<dc:title xml:lang="es">Límites de la medicación oral y transdérmica convencional en la enfermedad de Parkinson</dc:title>
<dc:subject>^d28214</dc:subject>
<dc:subject>^d55658</dc:subject>
<dc:subject>^d4871^s22073</dc:subject>
<dc:subject>^d28634</dc:subject>
<dc:subject>^d24230^s22000</dc:subject>
<dc:subject>^d23948^s22073</dc:subject>
<dc:subject>^d7453</dc:subject>
<dc:subject>^d23948^s22079</dc:subject>
<dc:subject>^d4871^s22078</dc:subject>
<dc:subject>^d10489^s22057</dc:subject>
<dc:subject>^d7366^s22000</dc:subject>
<dc:subject>^d982^s22000</dc:subject>
<dc:subject>^d19054</dc:subject>
<dc:subject>^d32276^s22073</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28622</dc:subject>
<dc:subject>^d4871^s22000</dc:subject>
<dc:subject>^d24230^s22073</dc:subject>
<dc:subject>^d7366^s22073</dc:subject>
<dc:subject>^d23948^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2438</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:subject>^d286</dc:subject>
<dc:subject>^d982^s22073</dc:subject>
<dc:subject>^d32276^s22000</dc:subject>
<dc:subject>^d6360</dc:subject>
<dc:type>article</dc:type>
<dc:date>201212</dc:date>
</metadata>
</record>
</ibecs-document>
